Insulin Pumps and Glucose Sensors in Diabetes Management
|
|
- Sheila Collins
- 6 years ago
- Views:
Transcription
1 Diabetes Update Congress Whistler, British Columbia Friday March 21, 2014ǀ 8:15 8:45 am Insulin Pumps and Glucose Sensors in Diabetes Management Bruce A Perkins MD MPH Division of Endocrinology Associate Professor and Clinician-Scientist
2 Dualities of Interest Disclosure (Commercial Entities) Speaker Fees: Glaxo Smith Kline, Inc; Medtronic Minimed, Inc; Johnson and Johnson-Animas; Roche; Eli Lilly Canada; Novo Nordisk; Sanofi Research Support Medtronic Minimed, Inc; Boehringer Ingelheim; Novo Nordisk Advisory Panel Neurometrix, Inc.
3 Key Objectives: In these next 25 minutes, you will PUMPS and CGM PUMPS IN CONTEXT CGM TECHNOLOGY Be able to cite the key studies that support use of CGM in clinical practice. Understand some of the methodological limitations of CGM and Pump RCTs. Describe the 2013 publications focused on strategies for hypoglycemia prevention SAP & CGM-SPECIFIC STUDIES HYPO PREVENTION STRATEGIES SUMMARY
4 The Diabetes Control and Complications Trial 1 (DCCT) Provides Best Evidence to Date for Intensive Management but long-term adherence was difficult once the study ended More Need self-management for novel strategies How do we reconcile the problem of long-term adherence to glycemic control? 1 DCCT/EDIC Research Group. N Engl J Med. 2000;342:381-9.
5 Audience Question In a T1D patient on MDI and suboptimal A1c, you anticipate the least A1c reduction from which of the following interventions: 1. Insulin pump therapy 2. Stand-alone CGM 3. Sensor-augmented pump therapy
6 Studies of Pump Therapy Alone in T1D: Pump Therapy vs. MDI Trials, Outcome A1c PUMPS and CGM PUMPS IN CONTEXT CGM TECHNOLOGY SAP & CGM-SPECIFIC STUDIES HYPO PREVENTION STRATEGIES SUMMARY Comment on T2D Misso ML et al, Cochrane Database Syst Rev Jan
7
8 Enzyme-based technology PUMPS and CGM PUMPS IN CONTEXT CGM TECHNOLOGY SAP & CGM-SPECIFIC STUDIES HYPO PREVENTION STRATEGIES SUMMARY Gluconic Acid Glucose + O 2 H 2 O 2 + Gluconic Acid H 2 O V H 2 O + 2 e - Boyne et al. Diabetes 2003
9 PUMPS and CGM PUMPS IN CONTEXT CGM TECHNOLOGY SAP & CGM-SPECIFIC STUDIES HYPO PREVENTION STRATEGIES SUMMARY Langendan M et al. CGM systems for T1DM (Systematic Review). Cochrane Database 2012.
10 Key Point #1 Evidence Strongly Supports the use of CGM to Augment Pump Therapy PUMPS and CGM PUMPS IN CONTEXT CGM TECHNOLOGY SAP & CGM-SPECIFIC STUDIES HYPO PREVENTION STRATEGIES SUMMARY Langendan M et al. CGM systems for T1DM (Systematic Review). Cochrane Database 2012.
11 A1C Primary Endpoint: A1C Reduction for SAP and MDI for All Patients (N = 485) 8.5% 8.0% 8.3% 8.0% 8.0% 8.1% 8.1% P< % 7.0% 7.5% 7.5% 7.5% 7.3% Months = SAP = MDI n = 244 n = 241 Maximal A1C reduction was correlated with sensor use in post-hoc analysis A1c reduction durable to 18 months in a non-randomized continuation phase Comparisons between SAP group and MDI group are significant for each time period (P<0.001). Bergenstal, et al. N Engl J Med Bergenstal, et al. Diabetes Care 2011
12 AUC (mg / dl x min) AUC (mg / dl x min) AUC for Hyper- and Hypoglycemia: All Patients Hyperglycemia AUC (>180 mg/dl or >10mM) Hypoglycemia AUC (< 70 mg/dl or <4mM) 40 p< p = Extent & duration of hyperglycemia in SAP was a third lower compared to MDI but not so for hypoglycemia Baseline 1 Year 0 Baseline 1 Year = SAP = MDI n = 247 n = 248 Comparisons between SAP group and MDI group are significant for each time period (P<0.001). Bergenstal, et al. N Engl J Med. 2010;363:
13 Eurythmics Study N= 83 in 8 European centres, A1c > 8.2% PUMPS and CGM PUMPS IN CONTEXT CGM TECHNOLOGY SAP & CGM-SPECIFIC STUDIES HYPO PREVENTION STRATEGIES SUMMARY Hermanides Diabetic Medicine 2011
14 Key Point #1a Evidence to Support SENSOR AUGMENTED PUMP is substantial. Hermanides Diabetic Medicine 2011
15 Studies of the Effect of CGM Alone (in patients with A1c 7-10%) Major Benefit in Adults JDRF Continuous Glucose Monitoring Study Group. N Engl J Med JDRF Continuous Glucose Monitoring Study Group. Diabetes Care 2009 PUMPS and CGM n=98 PUMPS IN CONTEXT CGM TECHNOLOGY 0.53%, P<0.001 SAP & CGM-SPECIFIC STUDIES HYPO PREVENTION STRATEGIES SUMMARY 6 month study, N=322. Insignificant effect of CGM on younger subgroups (n=224) A separate report of 129 subjects with A1c <7.0% showed substantial benefit in a composite outcome including hypoglycemic events
16 Studies of the Effect of CGM Alone in the context of SAP - SWITCH STUDY PUMPS and CGM * PUMPS IN CONTEXT CGM TECHNOLOGY SAP & CGM-SPECIFIC STUDIES Adult (n=81) Pediatric (n=72) Overall (n=153) HYPO PREVENTION STRATEGIES SUMMARY *p< N=153 in 4 European Centres, pump patients with inclusion criteria otherwise similar to STAR 3 Battelino Diabetologia. 2012
17 Key Point #2: The Evidence Supports a Moderate Independent Effect of CGM on A1c Reduction Treat to target* Body of evidence summary for A1c reduction: RealTrend* CGM Alone: % over 6 months SAP: 0.6 to 0.7 % over 6-12 months compared to MDI -0.43% (-0.32 to -0.55; P<0.001) *Pump Studies, akin to Switch Battelino Diabetologia. 2012
18 Messages from the 150-page Cochrane Review (Continued) PUMPS and CGM PUMPS IN CONTEXT CGM TECHNOLOGY Key Point #3: Evidence for the intermittent use of real time CGM reflects the results of the Switch Study in which the A1c benefit is lost after continuous use is stopped.* Key Point #4: Evidence for retrospective (blinded) CGM is very limited but does not support A1c benefit. SAP & CGM-SPECIFIC STUDIES HYPO PREVENTION STRATEGIES *Exception: GuardControl Study demonstrated good short-term A1c effect from bi-weekly sensor use. SUMMARY Deiss D GuardControl Study. Diabetes Care. 2006
19 Audience Question Use of an automated basal shut-off algorithm with sensoraugmented pump therapy accomplishes which of the following: 1. Reduces A1c more than SAP alone 2. Prevents hypo only in high-risk patients 3. Prevents day- and night-time hypoglycemia 4. Increases DKA risk
20 The ASPIRE In-Home trial (Automation to Simulate Pancreatic Insulin Response) Average Patient: 43yo with 27years of T1DM, A1c 7.2%, no recent severe hypo or hospitalization, and wore a sensor 80% of the time in a run-in period. Design: 3-month (2w run-in) randomized, controlled, multi-center, open-labelled trial N= 247. Primary Endpoint (Efficacy): AUC 10p-8a HYPO INTERVENTION SAP with Low Glucose Suspend LGS set at < 3.9 mmol/l CONTROL Standard SAP No LGS Bergenstal RM et al for the ASPIRE In-Home Study Group. N Engl J Med 2013;369:
21 Efficacy PUMPS and CGM Safety PUMPS IN CONTEXT CGM TECHNOLOGY SAP & CGM-SPECIFIC STUDIES HYPO PREVENTION STRATEGIES SUMMARY Number of Discrete Events decreased by 30%: Nocturnal 1.5 vs. 2.2 events per patient week Combined 3.3 vs. 4.7 events per patient week Severe hypoglycemia: 0 vs. 4 total events in the control. Extent & duration of hyperglycemia in LGS/TS was a third (38%) lower compared to Control Bergenstal RM et al for the ASPIRE In-Home Study Group. N Engl J Med 2013;369:
22 Sensor Glucose Values Before, During and After the 2-Hour Low risk of severe rebound Nocturnal hyperglycemia Suspends with LGS 9.4 mmol/l 3.9 mmol/l 5.1 mmol/l There were no DKA events Bergenstal RM, Klonoff DC, Garg SK, et al for the ASPIRE In-Home Study Group. Threshold-based insulin-pump interruption for reduction of hypogylycemia. N Engl J Med 2013;369: Bergenstal RM et al for the ASPIRE In-Home Study Group. N Engl J Med 2013;369:
23 PUMPS and CGM PUMPS IN CONTEXT CGM TECHNOLOGY SAP & CGM-SPECIFIC STUDIES HYPO PREVENTION STRATEGIES SUMMARY Average Patient: 18yo with 11years of T1DM, A1c 7.5%, on pump and with NEAR-TOTAL LOSS OF HYPOGLYCEMIA AWARENESS. Design: 6-month randomized, controlled, multi-center, openlabelled trial N= 95. Primary Endpoint (Efficacy): moderate (assistance) to severe (seizure/coma)hypoglycemia episodes Ly et al. JAMA Sept 26, 2013
24 Incidence Rates of Moderate-Severe Hypoglycemia *(Adjusted to baseline rates) 70% lower Average Percentage of hours spent in SG <3.9 Nocturnal 4.4 vs % Daytime 4.1 vs. 6.9 % Bergenstal RM, Klonoff DC, Garg SK, et al for the ASPIRE In-Home Study Group. Threshold-based insulin-pump interruption for reduction of hypogylycemia. N Engl J Med 2013;369: Ly et al. JAMA Sept 26, 2013
25 We can implement Technological Awareness now. PUMPS and CGM PUMPS IN CONTEXT CGM TECHNOLOGY SAP & CGM-SPECIFIC STUDIES HYPO PREVENTION STRATEGIES SUMMARY Courtesy of Richard Bergenstal.
26 Antecedent Hypoglycemia Challenges Both Physiological and Technological Awareness. Garg et al. The Order Effect in the ASPIRE In-Clinic Study. DT&T 2014
27 Approaches to overcome the challenge of A1c Reduction: Trials of PUMP THERAPY ALONE Minor A1c reduction (0.25% over 3-12 months) PUMPS and CGM PUMPS IN CONTEXT CGM TECHNOLOGY SAP & CGM-SPECIFIC STUDIES HYPO PREVENTION STRATEGIES SUMMARY Trials of CONTINUOUS GLUCOSE MONITORING ALONE Minor-moderate A1c reduction ( % over 6 months) Trials of SENSOR-AUGMENTED PUMP THERAPY vs. MDI More marked A1c reduction ( % over 6-12 months) Approaches to overcome the challenge of Hypoglycemia Reduction: THRESHOLD-BASED PUMP SUSPENSION is associated with substantially lower risk of minor (30-40%) and major (70%) hypoglycemia incidence, intensity and duration. Reality Check: Benefits need to be balanced by the increased technological demands on the patient.
28 Toll-free
Presented by Dr. Bruce Perkins, MD MPH Dr. Michael Riddell, PhD
Type 1 Diabetes and Exercise: Optimizing the Medtronic MiniMed Veo Insulin Pump and Continuous Glucose Monitoring (CGM) for Better Glucose Control 1,2 for Healthcare Professionals Presented by Dr. Bruce
More informationPREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS)
PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS) Pathways for Future Treatment and Management of Diabetes H. Peter Chase, MD Carousel of Hope Symposium Beverly Hilton, Beverly
More informationWhat is a CGM? (Continuous Glucose Monitor) The Bionic Pancreas Is Coming
The Bionic Pancreas Is Coming Montana Diabetes Professional Conference October 23, 2014 H. Peter Chase, MD Professor of Pediatrics University of Colorado Barbara Davis Center Stanford: Bruce Buckingham,
More informationReduction in Hypoglycemia and No Increase in A1C with Threshold-Based Sensor-Augmented Pump (SAP) Insulin Suspension: ASPIRE In-Home
Reduction in Hypoglycemia and No Increase in A1C with Threshold-Based Sensor-Augmented Pump (SAP) Insulin Suspension: ASPIRE In-Home Richard M. Bergenstal 1, David C. Klonoff 2, Bruce W. Bode 3, Satish
More informationCAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION
CAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS 2016 Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION September 9-11, 2016 ~ Sonesta Resort ~ Hilton Head Island, SC This continuing
More informationThe Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections
8/5/217 The Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections Richard M. Bergenstal, MD Executive Director International Diabetes Center at Park Nicollet Minneapolis,
More informationArtificial Pancreas Device Systems. Populations Interventions Comparators Outcomes. pump. pump
Protocol Artificial Pancreas Device Systems (10130) Medical Benefit Effective Date: 04/01/18 Next Review Date: 01/19 Preauthorization Yes Review Dates: 03/15, 03/16, 03/17, 01/18 Preauthorization is required.
More informationArtificial Pancreas Device Systems. Populations Interventions Comparators Outcomes Individuals: With type 1 diabetes
Protocol Artificial Pancreas Device Systems Medical Benefit Effective Date: 07/01/18 Next Review Date: 01/20 Preauthorization Yes Review Dates: 03/15, 03/16, 03/17, 01/18, 05/18, 01/19 Preauthorization
More informationArtificial Pancreas Device System (APDS)
Medical Policy Manual Durable Medical Equipment, Policy No. 77 Artificial Pancreas Device System (APDS) Next Review: October 2019 Last Review: October 2018 Effective: November 1, 2018 IMPORTANT REMINDER
More informationDiabetes Management: Current High Tech Innovations
Diabetes Management: Current High Tech Innovations How Far We ve Come in the Last 40 Years William V. Tamborlane, MD Department of Pediatrics Yale School of Medicine Disclosures I am a consultant for:
More informationControl of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim
Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim Division of Endocrinology and Metabolism, Samsung Medical Center, Sungkyunkwan University School of Medicine Conflict of interest
More informationComparing the use of SMBG vs. CGM data to Optimize Glucose Control in T2DM
Comparing the use of SMBG vs. CGM data to Optimize Glucose Control in T2DM For the first time using CGM to assess glucose control achieved in both groups Richard M. Bergenstal, MD International Diabetes
More informationHow I use the latest technology to investigate and treat a person with Type 1 Diabetes. Dr Pratik Choudhary
How I use the latest technology to investigate and treat a person with Type 1 Diabetes Dr Pratik Choudhary Disclosures Advisory board and speaker fees from Medtronic, Roche, Abbott and Johnson and Johnson,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bergenstal RM, Klonoff DC, Garg SK, et al. -based insulin-pump
More informationDiabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections. Aaron Michels MD
Diabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections Aaron Michels MD Outline SMBG & CGM by age group JDRF CGM Trial Sensor Augmented Insulin Pump Therapy for A1c Reduction
More informationClinical Value and Evidence of Continuous Glucose Monitoring
Clinical Value and Evidence of Continuous Glucose Monitoring 9402313-012 Objective To review the clinical value and the recent clinical evidence for Professional and Personal CGM Key Points CGM reveals
More informationOriginal Article. Nicholas B. Argento, MD 1 ; Katherine Nakamura, PhD 2 ABSTRACT
Original Article Nicholas B. Argento, MD 1 ; Katherine Nakamura, PhD 2 ABSTRACT Objective: Little information is available on personal real-time continuous glucose monitoring (PCGM) in patients 65 years
More informationThe In-Clinic Close Loop Experience in the US
The In-Clinic Close Loop Experience in the US Keystone Symposium, Practical Ways to Achieve Targets in Diabetes Care July 14, 2012 Francine Ratner Kaufman, MD Chief Medical Officer, VP Global Medical,
More informationPaolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna. Ipoglicemie e Monitoraggio Glicemico
Paolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna Ipoglicemie e Monitoraggio Glicemico Management of Hypoglycaemia.if hypoglycemia is a problem, the principles
More informationUpdate on Continuous Glucose Monitoring (CGM) Technology in Diabetes. Elena Toschi, MD November 12, 2016
Update on Continuous Glucose Monitoring (CGM) Technology in Diabetes Elena Toschi, MD November 12, 2016 Presenter Disclosure Information Elena Toschi, MD No financial disclosure Objectives: Use of CGM
More informationWhat is the role of insulin pumps in the modern day care of patients with Type 1 diabetes?
What is the role of insulin pumps in the modern day care of patients with Type 1 diabetes? Dr. Fiona Wotherspoon Consultant in Diabetes and Endocrinology Dorset County Hospital Fiona.Wotherspoon@dchft.nhs.uk
More informationAdvances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier?
Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier? Alan B Schorr DO FAAIM FACE www.sugardoc.com abs@sugardoc.com Disclosures
More informationArtificial Pancreas, shortly close to home? BC Pediatric Diabetes Day, Feb 26, 2016
Artificial Pancreas, shortly close to home? BC Pediatric Diabetes Day, Feb 26, 2016 Rémi Rabasa- Lhoret, M.D. (Endocrinology), Ph.D. CSPQ Director Pla:orm for Research in Obesity, Metabolism and Diabetes
More informationDiabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)
Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond) 9501366-011 20110401 Objectives Understand the need for insulin pumps and CGMS in managing
More informationAdvances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the US FDA estimated
More informationGlucose Control and Prevention of Cardiovascular Disease
Glucose Control and Prevention of Cardiovascular Disease Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Diabetes Update+, March
More informationEmerging Automated Insulin Delivery Systems
Emerging Automated Insulin Delivery Systems Richard M. Bergenstal, MD International Diabetes Center Park Nicollet & HealthPartners Minneapolis, MN Presenter Name 1 Dualities: Richard M. Bergenstal, MD
More informationMedical Policy. MP Artificial Pancreas Device Systems
Medical Policy MP 1.01.30 BCBSA Ref. Policy: 1.01.30 Last Review: 01/30/2018 Effective Date: 04/01/2018 Section: Durable Medical Equipment Related Policies 1.01.20 Continuous or Intermittent Monitoring
More informationWhen Will CGM Replace SMBG? Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida
When Will CGM Replace SMBG? Roy W. Beck, MD, PhD JAEB Center for Health Research Tampa, Florida Financial Disclosures Dr. Beck does not have any personal conflicts of interest His employer, the JAEB Center
More informationThe artificial pancreas: the next step in connectivity and digital treatment of type 1 diabetes
The artificial pancreas: the next step in connectivity and digital treatment of type 1 diabetes Roman Hovorka PhD FMedSci University of Cambridge, UK Duality of interest declaration Advisory Panel: Research
More informationAdvances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Insulin pump use: ~ 20% - 30% of patients with T1DM < 1% of insulin-treated patients with T2DM 2007 FDA estimates ~375,000 insulin pumps for
More informationHypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier??
Hypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier?? Moshe Phillip Institute of Endocrinology and Diabetes National Center of Childhood Diabetes Schneider
More informationArtificial Pancreas Device Systems
Artificial Pancreas Device Systems Policy Number: 1.01.30 Last Review: 1/2019 Origination: 1/2017 Next Review: 1/2020 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for
More informationCGM and Closing The Loop
CGM and Closing The Loop Dualities Research: Helmsely Charitable Trust, ADA, JDRF, NIDDK Consulting: Abbott Diabetes Care, Roche, Intarcia, Valeritas, Adocia, Big Foot Like With Pumps, We ve Come A Long
More informationInsulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness
Insulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness Prepared for: Agency for Healthcare Research and Quality (AHRQ) www.ahrq.gov Outline of Material Introduction
More informationNEWS BRIEFING Advances in Technology. moderated by: Irl Hirsch, MD University of Washington Medical Center
NEWS BRIEFING Advances in Technology moderated by: Irl Hirsch, MD University of Washington Medical Center 1 EMBARGO POLICY All recordings are for personal use only and not for rebroadcast online or in
More informationhypoglycaemia unawareness keystone 18 July 2014
hypoglycaemia unawareness keystone 18 July 2014 Hypoglycaemia unawareness: ( Impaired awareness of hypoglycaemia ) Philip Home Newcastle University Philip Home Duality of interest Manufacturers of glucose-lowering
More informationCGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER
CGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER Case 1: CGM use during pregnancy 29 yo G1P0000 at 10 5/7 weeks gestation presents to set
More informationGli inibitori di SGLT-2 possono essere impiegati nel diabete di tipo 1?
Impatto degli inibitori di SGLT-2 nei pazienti con diabete di tipo 2 Corso SID Hotel Michelangelo, Milano. 26 Giugno 2018 Gli inibitori di SGLT-2 possono essere impiegati nel diabete di tipo 1? Emanuele
More informationSensor-augmented pump systems provide insulin delivery
DIABETES TECHNOLOGY & THERAPEUTICS Volume 18, Number 10, 2016 Mary Ann Liebert, Inc. DOI: 10.1089/dia.2016.0216 ORIGINAL ARTICLE Effectiveness of Automated Insulin Management Features of the MiniMed c
More informationAdvances in Diabetes Care Technologies
Advances in Diabetes Care Technologies 1979 2015 Introduction Roughly 20% to 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the U.S. FDA
More informationType 1 DM. CME Away India & Sri Lanka March 23 - April 7, 2018
Type 1 DM CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright 2017 by Sea
More informationKing s Research Portal
King s Research Portal DOI: 10.1089/dia.2017.0051 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA):
More informationInsulin Pump Therapy in children. Prof. Abdulmoein Al-Agha, FRCPCH(UK)
Insulin Pump Therapy in children Prof. Abdulmoein Al-Agha, FRCPCH(UK) aagha@kau.edu.sa Highlights Evolution of insulin pump Pumps mimics Pancreas Goals of diabetes care What lowers HbA1c Criteria for selection
More informationUpdate on Diabetes Technology
Update on Diabetes Technology Andrew Ahmann, MD Professor of Medicine Director, Harold Schnitzer Diabetes Health Center OHSU Objectives: Recognize the growing role of technology in assisting patients and
More informationThe Realities of Technology in Type 1 Diabetes
The Realities of Technology in Type 1 Diabetes May 6, 2017 Rosanna Fiallo-scharer, MD Margaret Frederick, RN Disclosures I have no conflicts of interest to disclose I will discuss some unapproved treatments
More informationFlash Glucose Monitoring & Implantable Sensors
Flash Glucose Monitoring & Implantable Sensors Timothy Bailey, MD, FACE, CPI President & CEO, AMCR Institute Clinical Associate Professor, UCSD School of Medicine Disclosures Research Support: Abbott,
More informationVIRTUAL PATIENTS DERIVED FROM THE
VIRTUAL PATIENTS DERIVED FROM THE CARELINK DATABASE Benyamin Grosman PhD Senior Principle Scientist Medtronic Diabetes WHY VIRTUAL PATIENT MODELING? Reduce the cost of clinical trials Use models in conjunction
More informationUNO SGUARDO AL FUTURO. Basta la tecnologia a prevenire l ipoglicemia?
UNO SGUARDO AL FUTURO Basta la tecnologia a prevenire l ipoglicemia? Carmine G. Fanelli MISEM Azienda Ospedaliera Universitaria di Perugia Santa Maria della Misericordia Il sottoscritto dichiara di aver
More informationTechnology in Diabetes Management Irl B. Hirsch, MD University of Washington
Technology in Diabetes Management 2016 Irl B. Hirsch, MD University of Washington Dualities Research: Helmsley Charitable Trust, JDRF, ADA, NIDDK, CDC Consulting: Abbott, Roche, Intarcia Raise Your Hand
More informationContinuous Glucose Monitoring: Impact on Hypoglycemia
653411DSTXXX10.1177/1932296816653411Journal of Diabetes Science and Technologyvan Beers and DeVries research-article2016 Special Section Continuous Glucose Monitoring: Impact on Hypoglycemia Journal of
More informationT he benefits of intensive treatment of
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Effect of Continuous Glucose Monitoring on Hypoglycemia in Type 1 Diabetes TADEJ BATTELINO, MD, PHD 1 MOSHE PHILLIP,
More informationDiabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical
Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical Practice Guideline Task Force Members Anne Peters, MD (Chair)
More informationInpatient Studies of a Kalman-Filter-Based Predictive Pump Shutoff Algorithm
Journal of Diabetes Science and Technology Volume 6, Issue 5, September 2012 Diabetes Technology Society ORIGINAL ARTICLE Inpatient Studies of a Kalman-Filter-Based Predictive Pump Shutoff Algorithm Fraser,
More informationUpdates in Diabetes Technology
Updates in Diabetes Technology Jessica Kirk, MSN, RN, CPN, CDE Nurse Manager, Endo ECHO No disclosures Disclosures 1 Objectives Distinguish patients appropriate for continuous glucose monitoring and insulin
More informationCorporate Medical Policy
Corporate Medical Policy Continuous Monitoring of Glucose in the Interstitial Fluid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: continuous_monitoring_of_glucose_in_the_interstitial_fluid
More informationToday s Goals 10/6/2017. New Frontiers in Diabetes Technology. Disclosures
New Frontiers in Diabetes Technology Marie E. McDonnell, MD Director, Brigham and Women's Diabetes Program Division of Endocrinology, Diabetes and Hypertension Brigham and Women s Hospital Today s Goals
More informationThese comments are an attempt to summarise the discussions at the manuscript meeting. They are not an exact transcript.
1-Aug-2016 Dear Prof. Heller Manuscript ID BMJ.2016.034070 entitled "A cluster randomised trial comparing insulin pump therapy to multiple injections during flexible intensive insulin therapy for type
More informationFuture Direction of Artificial Pancreas. Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida
Future Direction of Artificial Pancreas Roy W. Beck, MD, PhD JAEB Center for Health Research Tampa, Florida Financial Disclosures Dr. Beck does not have any personal conflicts of interest His employer,
More informationTarget Audience. approach this patient case scenario, including identifying an
Activity Overview In this case-based webcast, meet LaWanda, a 57-year-old woman with type 2 diabetes. Her glycated hemoglobin (HbA1C) is 8.4%, she is currently taking basal insulin and fast-acting insulin,
More informationReport Reference Guide
Report Reference Guide How to use this guide Each type of CareLink report and its components are described in the following sections. Report data used to generate the sample reports was from sample patient
More informationFaculty Disclosure. No, nothing to disclose Yes, please specify: Novo-Nordisk. Roche. Abbott. Funded Research. Ownership/ Equity Position
Diabeloop Closed-Loop does better than sensor-augmented-pump on blood glucose during 3 days with intensive physical eercises: a randomized crossover trial. Sylvia Franc 1, MD, Sophie Borot, MD, PhD, Pierre-Yves
More informationReport Reference Guide. THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1
Report Reference Guide THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1 How to use this guide Each type of CareLink report and its components are described in the following sections.
More informationAdvances in Managing Diabetes in Youth. March 1, 2012
Advances in Managing Diabetes in Youth March 1, 2012 Diabetes in Youth: An Update The Problem Increasing Incidence of Type 1 Diabetes The Cause New Information on an Enterovirus connection New Therapy
More informationContinuous or Intermittent Glucose Monitoring in Interstitial Fluid
Continuous or Intermittent Glucose Monitoring in Interstitial Fluid Policy Number: 1.01.20 Last Review: 9/2014 Origination: 11/2001 Next Review: 9/2015 Policy Blue Cross and Blue Shield of Kansas City
More informationMore Than 1 Year of Hybrid Closed Loop in Pediatrics. Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center
More Than 1 Year of Hybrid Closed Loop in Pediatrics Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center Disclosure Dr. Forlenza has served as a consultant for Abbott Diabetes Care and conducts
More informationNorbert Hermanns, PhD 1,2, Beatrix Schumann, MD 2, Bernhard Kulzer, PhD 1,2, and Thomas Haak, MD 1,2. Original Article
524105DSTXXX10.1177/1932296814524105Journal of Diabetes Science and TechnologyHermanns et al research-article2014 Original Article The Impact of Continuous Glucose Monitoring on Low Interstitial Glucose
More informationQUESTION 4. WHAT CLINICAL DATA ARE CURRENTLY AVAILABLE TO SUPPORT EXPANDED CGM COVERAGE BY PAYERS AS PERTAINS TO QUESTIONS 1 AND 3?
500 1 QUESTION 4. WHAT CLINICAL DATA ARE CURRENTLY AVAILABLE TO SUPPORT EXPANDED CGM COVERAGE BY PAYERS AS PERTAINS TO QUESTIONS 1 AND 3? WHAT ADDITIONAL DATA ARE NEEDED? AACE/ACE CGM Consensus Conference:
More informationExercise Prescription in Type 1 Diabetes
Exercise Prescription in Type 1 Diabetes Michael Riddell, PhD Professor, Muscle Health Research Centre and School of Kinesiology & Health Science, York University Senior Scientist, LMC Diabetes & Endocrinology,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Artificial Pancreas Device Systems Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Artificial Pancreas Device Systems Professional Institutional Original
More informationDIABETES ADVOCATES TAKE ACTION!
DIABETES ADVOCATES TAKE ACTION! TELL CALIFORNIA STATE LEGISLATORS TO SUPPORT AB 447 MEDI-CAL COVERAGE OF CONTINUOUS GLUCOSE MONITORING (CGM) THERAPY FOR HIGH RISK DIABETICS This toolkit provides instructions
More informationCareLink. software REPORT REFERENCE GUIDE. Management Software for Diabetes
CareLink Management Software for Diabetes software REPORT REFERENCE GUIDE How to use this guide Each type of CareLink report and its components are described in the following sections. Report data used
More informationInsulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products
Insulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products FDA LABELED INDICATIONS 1-13,16-20 Rapid-Acting Indication Onset Peak Duration Insulins Fiasp (insulin
More informationObjective: Established methods of self-monitoring of glucose levels include capillary self-monitoring of blood glucose (SMBG) and
Flash Continuous Glucose Monitoring and its IMPACT to REPLACE Blood Glucose Monitoring in the Management of Type 1 and Type 2 Diabetes Stephen M Twigg, 1 Mahmood R Kazemi, 2 and Maria E Craig 3 1. Central
More informationDiabetes Care 34: , 2011
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Use of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes on Multiple Daily Injections Versus Continuous
More informationAdvances Towards the Bionic Pancreas.
Advances Towards the Bionic Pancreas. Ron Brazg MD, FACE Rainier Clinical Research Center Renton, WA DISCLOSURES Rainier Clinical Research Center is an independent research facility not directly affiliated
More informationContinuous Glucose Monitoring (CGM)
Continuous Glucose Monitoring (CGM) Background Info A1c Average glucose levels over previous 2-3 months Currently remains gold standard for determining control Indicator of risk for development of complications
More informationIn general: Hypoglycemia is common in insulin treated diabetes, but may also occur in people on oral medications, especially sulfonylureas/glinides.
1 2 3 In general: Hypoglycemia is common in insulin treated diabetes, but may also occur in people on oral medications, especially sulfonylureas/glinides. 4 Answer: b and c Many alcohol containing drinks
More informationACCORD, ADVANCE & VADT. Now what do I do in my practice?
ACCORD, ADVANCE & VADT Now what do I do in my practice? Richard M. Bergenstal, MD International Diabetes Center Park Nicollet Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com
More informationHybrid Closed Loop Status & Practical Challenges in Implementation
Hybrid Closed Loop Status & Practical Challenges in Implementation Bruce Buckingham, MD Buckingham@Stanford.edu Professor of Pediatric Endocrinology Stanford School of Medicine Conflict of Interests Company
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Artificial Pancreas Device Systems Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Artificial Pancreas Device Systems Professional Institutional Original
More informationBasics of Continuous Subcutaneous Insulin Infusion Therapy. Lubna Mirza, MD Norman Endocrinology Associates 2018
Basics of Continuous Subcutaneous Insulin Infusion Therapy Lubna Mirza, MD Norman Endocrinology Associates 2018 Preamble Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationNCT Number: NCT
Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec 100 U/mL in insulin-naïve adults with type 2 diabetes mellitus: Design and baseline characteristics of the BRIGHT study Alice Cheng
More informationDiabetes Technology Update. Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018
Diabetes Technology Update Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018 Disclosures None No future technologies are FDA approved Continuous Glucose Monitors Continuous Glucose Monitors
More informationNEWS BRIEFING Adjunctive Therapies in Type 1 and Type 2 Diabetes
NEWS BRIEFING Adjunctive Therapies in Type 1 and Type 2 Diabetes Moderated by: Bernard Zinman, MD, CM, FRCPC, FACP Lunenfeld-Tanenbaum Research Institute and University of Toronto Mount Sinai Hospital
More informationSponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationInsulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products
Insulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products FDA LABELED INDICATIONS 1-13,16-21 Rapid-Acting Indication Onset Peak Duration Insulins Admelog (insulin
More informationDescription. Section: Durable Medical Equipment Effective Date: July 15, 2014 Subsection: Original Policy Date: December 7, 2011 Subject:
Last Review Status/Date: June 2014 Page: 1 of 13 Description Tight glucose control in patients with diabetes has been associated with improved outcomes. Several devices are available to measure glucose
More informationPreventing Hypoglycemia Using Predictive Alarm Algorithms and Insulin Pump Suspension
DIABETES TECHNOLOGY & THERAPEUTICS Volume 11, Number 2, 29 Mary Ann Liebert, Inc. DOI: 1.189/dia.28.32 Preventing Hypoglycemia Using Predictive Alarm Algorithms and Insulin Pump Suspension Bruce Buckingham,
More informationControl of Blood Glucose in the ICU: Reconciling the Conflicting Data
Control of Blood Glucose in the ICU: Reconciling the Conflicting Data Steven E. Nissen MD Disclosure Consulting: Many pharmaceutical companies Clinical Trials: AbbVie, Amgen, Astra Zeneca, Esperion, Eli
More informationClinical practice guidelines in management of type 1 diabetic patients
2016 International Conference on Diabetes and Metabolism October 13 ~ 15, 2016, Grand Hilton Seoul Hotel, Korea S2 Behavioral medicine/education : Current management of type 1 diabetes in real clinical
More informationEarly Patient and Clinician Experiences with Continuous Glucose Monitoring
Feature Article / Early Experiences with CGM Early Patient and Clinician Experiences with Continuous Glucose Monitoring David K. Bloomgarden, MD, FACE; Janine Freeman, RD, LD, CDE; and Elizabeth DeRobertis,
More informationWOULD YOU LIKE MORE CONFIDENCE IN YOUR HYPOGLYCAEMIC CONTROL? SMARTGUARD. PROVIDES PREDICTIVE PROTECTION
WOULD YOU LIKE MORE CONFIDENCE IN YOUR HYPOGLYCAEMIC CONTROL? SMARTGUARD. PROVIDES PREDICTIVE PROTECTION 1,2 MINIMED 640G WITH SMARTGUARD HAVE YOU CONSIDERED THE REAL IMPACT HYPOGLYCAEMIA HAS ON YOUR LIFE?
More informationAdherence to therapy. Kamlesh Khunti University of Leicester, UK. William Polonsky University of California San Diego, USA
Adherence to therapy Kamlesh Khunti University of Leicester, UK William Polonsky University of California San Diego, USA 1 Dualities of interest Kamlesh Khunti: Honoraria for speaking, advising or research
More information8/5/2017. Disclosure to Participants. What is PCORI? Outline. To Test or Not To Test. What is PCORI? THE MONITOR TRIAL
THE MONITOR TRIAL Effect of Glucose Monitoring on Patient and Provider Outcomes in Non-insulin Treated Diabetes Laura Young, MD, PhD Assistant Professor of Medicine University of North Carolina To Test
More informationSensor-augmented insulin pump with automated low-glucose insulin suspension has the potential to reduce the incidence of major hypoglycemic events.
Research Original Investigation Effect of Sensor-Augmented Insulin Pump Therapy and Automated Insulin Suspension vs Standard Insulin Pump Therapy on Hypoglycemia in Patients With Type 1 Diabetes A Randomized
More informationThe next five years in diabetes technology: closed-loop systems
The next five years in diabetes technology: closed-loop systems J. H. (Hans) DeVries Academic Medical Center at the University of Amsterd, the Netherlands Keystone, CO, 19 July 2013 Disclosure AP@home,
More informationPOLICIES AND PROCEDURE MANUAL
POLICIES AND PROCEDURE MANUAL Policy: MP071 Section: Medical Benefit Policy Subject: Continuous Subcutaneous Glucose Monitor CSGM I. Policy: Continuous Subcutaneous Glucose Monitor (CSGM) II. Purpose/Objective:
More information